mAbxience, Sandoz to develop emicizumab biosimilar; exclusive rights
mAbxience and Sandoz agreed to develop, manufacture and commercialize an emicizumab biosimilar. Sandoz holds exclusive global rights excluding Argentina, Uruguay and Paraguay.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.